Alembic receives FDA OK for generic Toradol
Ketorolac tromethamine is indicated for the short-term management of moderately severe acute pain in adult patients.
Alembic has received the Food and Drug Administration’s nod for ketorolac tromethamine injection, 15 mg/ml, 30 mg/ml, and 30 mg/ml single-dose vials.
The drug is the generic of Toradol, which is indicated for the short-term management of moderately severe acute pain in adult patients.
[Read more: Alembic intros generic Perforomist]
Ketorolac tromethamine injection had a market value of roughly $59 million for the 12 months ending June 2022, according to IQVIA.